RxDoctor Payments Data

Michael Yoesel, MD

Family Medicine · Colorado Springs, CONPI 1164462297

Payments from drug & device makers

$510in general payments, 2019–2025

Across 24 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cleerly, Inc.$130
  • Amgen$62
  • Astellas Pharma US Inc$59
  • AstraZeneca$55
  • Novo Nordisk$33
  • Gilead$21
  • plus $149 from 10 others

What the payments were for

  • Food & beverage$510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 70th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$96,319
Medicare patients
253
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$38,276
JardianceEmpagliflozin40$31,833
OzempicSemaglutide31$29,845
Spiriva RespimatTiotropium Bromide14$19,904
XareltoRivaroxaban13$17,731
Breo ElliptaFluticasone/Vilanterol11$12,405
LyricaPregabalin12$9,500
Praluent PenAlirocumab11$9,058
Xtampza ErOxycodone Myristate12$8,810
TradjentaLinagliptin12$6,631
SymbicortBudesonide/Formoterol Fumarate17$5,995
SynthroidLevothyroxine Sodium36$5,129
Rosuvastatin Calcium374$3,387
Atorvastatin Calcium357$3,236
OsphenaOspemifene12$3,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$17$58,36866 claims
PfizerEliquis, Lyrica$13$47,77651 claims
Novo NordiskOzempic$33$29,84531 claims
Johnson & JohnsonXarelto$12$17,73113 claims
AstraZenecaSymbicort$55$5,99517 claims
AbbVieSynthroid$17$5,12936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →